Fukushima Medical University

WASHINGTON, Sept. 24, 2025 /PRNewswire/ -- The Association for the Accreditation of Human Research Protection Programs has awarded full accreditation to ACTIVATO of Sendai, Miyagi, Japan. The nonprofit independent institutional review board is the third research organization in Japan to commit to AAHRPP's standards for research ethics and protections. ACTIVATO serves as the research ethics review board for seven university hospitals in the Tohoku region: Hirosaki University School of Medicine, Akita University School of Medicine, Iwate Medical University Hospital, Yamagata University School of Medicine, Fukushima Medical University, Tohoku University of Medical and Pharmaceutical Sciences, and Tohoku University Hospital. The IRB reviews clinical trials within and outside Japan. "In today's global research enterprise, AAHRPP accreditation is more important and more impactful than ever," AAHRPP President and CEO Elyse Summers said. "With 600+ accredited entities around the world, AAHRPP's standards play a key role in safeguarding research participants and advancing high-quality, ethical research." AAHRPP also approved reaccreditation of the following: To earn accreditation and reaccreditation, organizations must demonstrate that they have built extensive safeguards into every level of their research operation, adhere to high standards for research, and are committed to continuous improvement. In today's increasingly collaborative research environment, accreditation status can provide added assurance and a competitive edge. AAHRPP has accredited research entities across the U.S. and in Australia, Belgium, Brazil, Canada, China, India, Japan, Jordan, Mexico, Republic of Korea, Saudi Arabia, Singapore, Taiwan, Thailand, and United Arab Emirates. To learn more, visit . FOR MORE INFORMATION CONTACT: Michelle Feige Executive Vice President [email protected] 202-783-1112 SOURCE Association for the Accreditation of Human Research Protection Programs WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

DUBLIN--( BUSINESS WIRE )--The "Protein Microarrays - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Protein Microarrays was estimated at US$4.6 Billion in 2023 and is projected to reach US$7.2 Billion by 2030, growing at a CAGR of 6.8% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The growth in the protein microarrays market is driven by several factors. The increasing demand for high-throughput proteomics tools in drug discovery and development is a major growth driver, as pharmaceutical companies are relying more on protein microarrays for rapid screening of potential drug candidates. Technological advancements, such as label-free detection methods and AI-driven data analysis, are enhancing the accuracy and efficiency of protein microarrays, further encouraging their adoption in research settings. The rise of personalized medicine is also expanding the use of protein microarrays in clinical diagnostics, as healthcare providers seek to tailor treatments based on individual protein profiles. Additionally, the growing need for biomarker identification in cancer, autoimmune diseases, and infectious diseases is propelling the demand for protein microarrays in both research and clinical applications. Lastly, government initiatives and funding for proteomics research are supporting the continued growth of the protein microarrays market, particularly in academic and research institutions. What Are the Key Industry and Healthcare Trends Impacting Protein Microarrays? The growing interest in personalized medicine and precision diagnostics is a significant factor in the rising demand for protein microarrays. Healthcare providers are increasingly relying on molecular profiling tools, such as protein microarrays, to deliver more targeted and effective treatments. This trend is particularly evident in oncology, where protein microarrays are used to identify cancer-specific biomarkers and monitor treatment responses. The pharmaceutical industry is also a major driver of the protein microarrays market, as these tools are used in drug discovery to screen for protein interactions that could lead to new therapeutic targets. Additionally, the rising prevalence of chronic diseases, such as diabetes and cardiovascular disorders, has increased the demand for advanced diagnostic technologies capable of providing detailed insights into protein expression and metabolic pathways. The expansion of research in immunology, autoimmune diseases, and infectious diseases is further boosting the adoption of protein microarrays for understanding complex protein interactions in disease contexts. Key Insights: Market Growth: Understand the significant growth trajectory of the Analytical Microarrays segment, which is expected to reach US$4.6 Billion by 2030 with a CAGR of a 7.0%. The Functional Microarrays segment is also set to grow at 6.3% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, which was estimated at $1.2 Billion in 2023, and China, forecasted to grow at an impressive 10.9% CAGR to reach $1.6 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of major players in the Protein Microarrays market such as Antigen Discovery, Arrayit Corporation, Bio-Rad Laboratories, Inc., Cambridge Protein Arrays, Columbia Biosciences Corporation and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. Key Attributes: Report Attribute Details No. of Pages 186 Forecast Period 2023 - 2030 Estimated Market Value (USD) in 2023 $4.6 Billion Forecasted Market Value (USD) by 2030 $7.2 Billion Compound Annual Growth Rate 6.8% Regions Covered Global Key Topics Covered: MARKET OVERVIEW Influencer Market Insights World Market Trajectories Impact of COVID-19 and a Looming Global Recession Protein Microarrays - Global Key Competitors Percentage Market Share in 2024 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E) MARKET TRENDS & DRIVERS Growing Demand for High-Throughput Proteomic Analysis Propels Growth in the Protein Microarrays Market Advancements in Microarray Technology and Precision Diagnostics Strengthen the Business Case for Protein Microarrays Increasing Use of Protein Microarrays in Biomarker Discovery Expands Addressable Market Opportunities Rising Demand for Personalized Medicine and Targeted Therapies Drives Adoption of Protein Microarrays Technological Innovations in Multiplexed Protein Detection Accelerate the Development of Protein Microarrays Integration of Artificial Intelligence (AI) and Machine Learning in Data Analysis Spurs Use of Protein Microarrays in Research Increasing Focus on Early Disease Detection and Diagnostics Generates Opportunities for Protein Microarray Applications Growing Investment in Drug Discovery and Development Expands Demand for Protein Microarrays in Pharmaceutical Research Increasing Prevalence of Chronic Diseases and Cancer Drives the Adoption of Protein Microarrays in Clinical Applications Expansion of Biopharmaceutical Research and Proteomics Strengthens Market for Protein Microarrays in Drug Development FOCUS ON SELECT PLAYERS: Some of the 48 companies featured in this Protein Microarrays market report include Antigen Discovery Arrayit Corporation Bio-Rad Laboratories, Inc. Cambridge Protein Arrays Columbia Biosciences Corporation Creative Biolabs Euroimmun AG Fraunhofer IZI-BB Fukushima Medical University GeneCopoeia, Inc. For more information about this report visit https://www.researchandmarkets.com/r/2w5lbt About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Tuning Fork Bio nods not only to the characteristic Y-shaped antibody, but also to Yamaha’s early history as a musical instrument maker. Start SEEING antibodies. Yamaha Motor Company—the Japanese manufacturer famous for its motorcycles, off-road vehicles and jet skis—is now setting its sights on molecular engines. It has established a new U.S. subsidiary, Tuning Fork Bio, with the goal of entering the antibody profiling business and providing diagnostic tests for health checkups and pharmaceutical research. Working in collaboration with researchers from Fukushima Medical University in Japan, the outfit plans to develop microarray technology capable of sifting through the tens of thousands of proteins that can be found within blood samples—to identify biomarkers that can be linked to not just specific diseases, but also the particular stages within a disease. The tests rely on the evidence created by the human body when the immune system deploys distinct antibodies that target and bind to the antigens found on invading viruses and bacteria.  The antibody analysis technology developed at Fukushima Medical’s Translational Research Center is able to transfer a high density of proteins to glass slides—built from a library of more than 20,000 representing different potential antigens, the company said. When a blood sample is applied to the slide, any antibodies present connect with their matching partner, creating patterns that can be linked to various infections or autoimmune conditions. The company said it plans to compare profiles between healthy and sick people to hopefully identify the hidden changes that occur within the body as a condition begins to take hold, with the ultimate goal of being able to direct them to more specific treatments. Tuning Fork—the name nodding not only to the characteristic Y-shaped antibody, but also to Yamaha’s early history as a musical instrument maker—will mainly focus on products for the U.S. and Japan, the company said, with its headquarters in Delaware and an R&D partner in a separate Tokyo-based subsidiary. The company is not Yamaha’s first foray into healthcare research. Alongside its catalog of powerboats, industrial robots and flying drones sits the Cell Handler sorting and imaging system, designed to isolate both single cells and larger organoids. Tuning Fork was born out of the company’s partnership with Fukushima Medical, which was the first user of the Cell Handler hardware. Yamaha said it has taken a strategic interest in the medical research and healthcare field and plans to eventually scale up its efforts into a future core business.